Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01168687 · ClinicalTrials.gov registry record · NA

Effects of Levetiracetam (Keppra) on Alcohol Consumption

A NA study of Alcohol Abuse and Drug Abuse, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
46
Enrollment target
1
Study location

NCT01168687: Completed NA study of Alcohol Abuse and Drug Abuse, sponsored by University of California, San Francisco.

NCT01168687 is a NA study of Alcohol Abuse and Drug Abuse that has completed, run by University of California, San Francisco. The registered enrollment target is 46 participants, below the 712-participant average among 46 other Alcohol Abuse trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01168687, a NA study of Alcohol Abuse and Drug Abuse, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

The overall goals of this study are to (1) expand knowledge about interactions of levetiracetam with alcohol by assessing the effects of levetiracetam compared to placebo in moderate and heavy social alcohol users and (2) to test the AccuswayTM platform as a tool to measure postural control (which has been used as a marker of intoxication) and the effects of levetiracetam on postural control.

Primary Outcome

The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Levetiracetam (Keppra)

Study Locations (1)

California

  • Children's Hospital Oakland Research Institute- CRC - Berkeley

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2008-11
Est. Completion 2010-11
Phase NA

What the finished NCT01168687 record still lists

NCT01168687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 712-participant average among 46 other Alcohol Abuse trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Alcohol Abuse appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01168687 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01168687 about?

NCT01168687 is a clinical study titled "Effects of Levetiracetam (Keppra) on Alcohol Consumption". The overall goals of this study are to (1) expand knowledge about interactions of levetiracetam with alcohol by assessing the effects of levetiracetam compared to placebo in moderate and heavy social alcohol users and (2) to test the AccuswayTM platform as a tool to measure postural control (which h...

What is the current status of trial NCT01168687?

This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2008-11. Estimated completion is 2010-11.

What conditions does trial NCT01168687 study?

This clinical trial studies the following conditions: Alcohol Abuse, Drug Abuse.

What interventions are being tested in trial NCT01168687?

The interventions under investigation include: Placebo (DRUG), Levetiracetam (Keppra) (DRUG).

Who is sponsoring clinical trial NCT01168687?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01168687 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01168687's enrollment target sits among peer trials

46 40th of 46 higher than 7 of 46 other Alcohol Abuse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01168687, the US trial registry maintained by the National Library of Medicine. NCT01168687 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.